RxDoctor Payments DataLook up a doctor →

Ian Flinn, MD

Hematology & Oncology · Nashville, TNNPI 1417990367

Payments from drug & device makers

$41,159,148in general payments, 2019–2025

Across 4,377 payments — averaging $9403.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$11.3M
  • Seagen Inc.$5.4M
  • AstraZeneca$5.2M
  • Genentech, Inc.$4.5M
  • Gilead$2.2M
  • Novartis$1.9M
  • plus $10.7M from 54 others
$62,536in research payments, 2019–2025

Across 27 payments — averaging $2316.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$25K
  • Eli Lilly$21K
  • Bristol Myers Squibb$14K
  • Acerta Pharma LLC$2K
  • Novartis$961
  • Gilead$109
  • plus $16 from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beigene, Ltd.649$11,321,615
Seagen Inc.195$5,394,345
AstraZeneca(2 entities)36$5,178,046
Genentech, Inc.466$4,476,994
Gilead(2 entities)667$2,244,770
Novartis58$1,868,766
Eli Lilly37$1,646,239
TG Therapeutics, Inc.482$1,566,147
AbbVie260$1,263,490
Acerta Pharma LLC46$851,078
Pharmacyclics LLC, An Abbvie Company316$833,122
Astrazeneca UK Limited24$697,634
Beone Medicines Ltd.19$676,658
Bristol Myers Squibb44$572,850
Incyte Corporation268$485,137
Merck12$451,639
Morphosys AG27$379,767
Janssen Research & Development, LLC119$288,119
Epizyme, Inc.67$142,825
Hoffmann-la Roche Limited28$138,044
Verastem, Inc.163$126,998
Beigene AUS Pty Ltd20$99,741
E.r. Squibb & Sons, L.L.C.16$93,785
Takeda Pharmaceuticals U.S.A., Inc.44$78,558
Agios Pharmaceuticals, Inc.53$60,346
Pfizer29$51,932
F. Hoffmann-la Roche AG32$50,594
Secura Bio, Inc.13$34,637
CTI Biopharma Corp.7$29,435
Beigene USA, Inc.15$12,646
Servier Pharmaceuticals LLC9$8,905
Novo Nordisk1$5,428
Sanofi7$5,104
Sobi, Inc6$4,862
Johnson & Johnson10$3,302
Genentech USA, Inc.16$3,239
Genmab U.S., Inc.7$3,219
Portola Pharmaceuticals, LLC8$3,046
Morphosys, US Inc.1$2,000
Beone Medicines USA, Inc.4$1,916
Amgen16$435
Astellas Pharma US Inc14$300
Lilly USA, LLC4$191
Daiichi Sankyo Inc.9$185
ADC Therapeutics America, Inc.7$171
Stemline Therapeutics Inc.3$160
Teva Pharmaceuticals USA, Inc.12$157
Rigel Pharmaceuticals, Inc.5$106
Pharmaessentia USA Corporation3$70
Spectrum Pharmaceuticals Inc.2$44
Dova Pharmaceuticals3$42
Jazz Pharmaceuticals Inc.2$37
Karyopharm Therapeutics Inc.2$33
Kyowa Kirin, Inc.2$29
Partner Therapeutics, Inc.2$27
Servier Bioinnovation1$25
Taiho Oncology, Inc.1$25
Ipsen Biopharmaceuticals, Inc1$21
GSK1$20
Bayer1$19

How this compares

$41,159,148 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,533,008
Medicare patients
255
Services billed
43,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →